Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)

ConclusionPM and DHEA improved vaginal symptoms at 12 weeks. However, vaginal DHEA, 6.5 mg, significantly improved sexual health. Vaginal DHEA warrants further investigation in women with a history of cancer.

http://link.springer.com/10.1007/s00520-017-3878-2

Source: Supportive Care in Cancer - January 3, 2018 Category: Cancer & Oncology Source Type: research